Skip Ribbon Commands
Skip to main content

UCHealth Home

:

Clinical Trials: A Phase Ib study of intermittent administration of high doses of the irreversible EGFR inhibitor afatinib as a means of achieving plasma levels active against non-small cell lung cancer with known T790M mutations

 


A Phase Ib study of intermittent administration of high doses of the irreversible EGFR inhibitor afatinib as a means of achieving plasma levels active against non-small cell lung cancer with known T790M mutations


Trial Focus

Lung Cancer

Objective

         Not available at this time

IRB Protocol #

12-0610

Trial Status

OPEN

Principle Investigator

ROSS CAMIDGE

Sponsor

Boehringer Ingelheim Pharmaceuticals, Inc.

Contact

TARA WELLS at (720)848-0755 or TARA.WELLS@UCDENVER.EDU

Location

University of Colorado Hospital University of Colorado Hospital

Eligibility and Other Participant Information


What To Expect : Not available at this time // Not available at this timeNot available at this time